{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=14&state=Utah", "query": { "state": "Utah", "city": "Salt Lake City", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1925, "total_pages": 193, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=15&state=Utah&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=13&state=Utah&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T03:45:55.071Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07845071", "title": "An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Cebranopadol 400 ug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adneuris Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 160, "start_date": "2026-09-22", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T09:06:50.324Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Riverside, California • Longmont, Colorado + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Riverside", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Savannah", "state": "Georgia" }, { "city": "O'Fallon", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07845071" }, { "nct_id": "NCT07659782", "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "VS-7375", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2026-07-22", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:38:45.641Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07659782" }, { "nct_id": "NCT07326566", "title": "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Cancer", "Central Nervous System Diseases", "GBM", "Glioblastoma (GBM)", "Glioblastoma Multiforme (GBM)", "Glioma", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "silevertinib in combination with temozolomide", "type": "DRUG" }, { "name": "temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Black Diamond Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2026-05-05", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:45:32.485Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07326566" }, { "nct_id": "NCT07293351", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Casdatifan", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2026-03-26", "completion_date": "2031-11-26", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T17:17:36.663Z", "location_count": 17, "location_summary": "Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07293351" }, { "nct_id": "NCT07252232", "title": "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Resectable Pancreatic Ductal Adenocarcinoma (PDAC)", "Resected Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "daraxonrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-12-15", "completion_date": "2030-07-10", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T23:00:41.684Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07252232" }, { "nct_id": "NCT07221357", "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Untreated, Unresectable, or Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 990, "start_date": "2025-12-31", "completion_date": "2034-03-11", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T17:35:37.397Z", "location_count": 46, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221357" }, { "nct_id": "NCT07198074", "title": "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Endometrial Carcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 255, "start_date": "2026-01-27", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:49:03.259Z", "location_count": 304, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07198074" }, { "nct_id": "NCT07063745", "title": "A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer With MTAP Deletion" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-01-02", "completion_date": "2031-08-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-28T03:45:55.071Z", "location_count": 44, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063745" }, { "nct_id": "NCT07020221", "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "G12D Mutated KRAS", "Non Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Solid Tumor, Adult" ], "interventions": [ { "name": "Carboplatin + Pemetrexed + Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Gemcitabine + Nab-paclitaxel", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "VS-7375", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2025-06-24", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T21:10:27.237Z", "location_count": 13, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07020221" }, { "nct_id": "NCT06963827", "title": "A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Disease" ], "interventions": [ { "name": "Mezagitamab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 347, "start_date": "2025-07-15", "completion_date": "2030-01-14", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-27T14:26:55.694Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06963827" } ] }